ProShares Ultra Nasdaq Biotechnology (BIB)
| Assets | $113.39M |
| NAV | $61.29 |
| Expense Ratio | 0.95% |
| PE Ratio | n/a |
| Shares Out | 1.85M |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Dec 22, 2022 |
| 1-Year Return | -19.32% |
| Volume | 27,195 |
| Open | 63.39 |
| Previous Close | 64.05 |
| Day's Range | 60.66 - 63.56 |
| 52-Week Low | 38.42 |
| 52-Week High | 85.18 |
| Beta | 1.61 |
| Holdings | 370 |
| Inception Date | Apr 8, 2010 |
About BIB
The ProShares Ultra Nasdaq Biotechnology (BIB) is an exchange-traded fund that is based on the NASDAQ / Biotechnology index. The fund provides 2x daily exposure to a modified market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ. BIB was launched on Apr 8, 2010 and is managed by ProShares.
Top 10 Holdings
144.07% of assets| Name | Symbol | Weight |
|---|---|---|
| NASDAQ BIO INDEX SWAP BNP | n/a | 27.06% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONAL | n/a | 22.95% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALE | n/a | 21.01% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AG | n/a | 18.31% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NA | n/a | 15.60% |
| NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NA | n/a | 13.57% |
| Gilead Sciences, Inc. | GILD | 7.69% |
| Amgen Inc. | AMGN | 6.51% |
| Vertex Pharmaceuticals, Inc. | VRTX | 5.69% |
| Regeneron Pharmaceuticals, Inc. | REGN | 5.68% |
News
Cap-Weighting Crucial When Indexing Biotech
The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in developm...
How to Invest in Biotech in 2022
It's been a hard year for a lot of the biotech industry, with many hedge funds ending the year with significant losses, but there have been a number of shining stars that are expected to continue to off...
Take a Look at the Top-Performing Biotech ETFs YTD
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
Could Biotech ETFs Get Another Boost From JNJ News?
This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This ...
Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs
Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
Pfizer-BioNTech COVID-19 Vaccine Garners Full FDA Approval
The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that officia...
Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval
There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be a...
As Covid Cases Mutate, the Biotech Industry Works to Keep Up
As the Delta variant sweeps across the globe, pharmaceutical and biotech companies are working to ensure vaccines continue to cover the population, as well as working on booster doses that can adapt to ...
Top-Performing Biotechnology ETFs Amid Coronavirus Outbreak
From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.
